Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses inhibitors for the nitration of amyloid-β (Aβ) peptides as a novel means to diagnose and treat Alzheimer's disease. The invention focuses on identifying and using inhibitors—such as small molecules, peptides, or specific antibodies—that prevent or reduce the aggregation of nitrated Aβ peptides, particularly by targeting the nitration of the tyrosine at position 10. The patent also covers methods to produce such inhibitors or antibodies, diagnostic kits to detect the aggregation status of Aβ, and the use of these tools to monitor and slow the progression of Alzheimer's disease, as well as animal models used for further research.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of new drugs that inhibit the aggregation of Aβ peptides to slow or prevent progression of Alzheimer's disease.
• Creation of diagnostic tests or kits to detect nitrated forms of Aβ in biological samples for early diagnosis and monitoring of Alzheimer's disease.
• Production of therapeutic antibodies targeting nitrated Aβ aggregates for clinical treatment of Alzheimer's and related neurodegenerative disorders.
• Use in research to screen libraries for effective inhibitors, further elucidating Alzheimer's pathology.
• Development of animal models (e.g., transgenic mice) for studying disease mechanisms and testing new treatments.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a novel therapeutic target—nitration of Aβ, specifically at tyrosine 10—for drug development in Alzheimer's disease, which has limited effective treatments.
• Enables early and specific diagnosis of Alzheimer's disease through detection of nitrated Aβ forms, potentially improving patient outcomes.
• Potential to slow or halt the progression of neurodegeneration and cognitive decline in Alzheimer's by inhibiting harmful Aβ aggregation.
• Facilitates the development of both therapeutics and diagnostics, supporting a comprehensive approach to Alzheimer's management.
• Offers tools (antibodies, animal models) for further research into Alzheimer's mechanisms, accelerating the discovery of future treatments.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a method for identifying an inhibitor of the aggregation of amyloid-² peptide (A²), comprising the steps of a) contacting at least one A²-peptide and/or the nitrated forms thereof with at least one candidate inhibitor that potentially specifically binds to a region in said A²-peptide capable of being nitrated, and b) detecting said inhibitor specifically binding to said region in said A²-peptide through detecting a lack of or a reduced aggregation of said at least one A²-peptide. The present invention is further directed at improved methods for treating neuronal degradation and particularly Alzheimer's disease, based on said inhibitor. The present invention is further directed at methods for diagnosing the aggregation of A²-peptide in the context of neuronal degradation and particularly Alzheimer's disease.